Fidelity Investments’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-4,133
| Closed | -$37.7K | – | 5557 |
|
|
2025
Q2 | $37.7K | Sell |
4,133
-4,130
| -50% | -$30.4K | ﹤0.01% | 4026 |
|
|
2025
Q1 | $65.7K | Sell |
8,263
-4,108,743
| -100% | -$30.1M | ﹤0.01% | 3736 |
|
|
2024
Q4 | $22.4M | Sell |
4,117,006
-1,154,102
| -22% | -$7.06M | ﹤0.01% | 1689 |
|
|
2024
Q3 | $38.1M | Sell |
5,271,108
-552,248
| -9% | -$5.06M | ﹤0.01% | 1484 |
|
|
2024
Q2 | $63.2M | Sell |
5,823,356
-44,927
| -0.8% | -$576K | ﹤0.01% | 1223 |
|
|
2024
Q1 | $110M | Buy |
5,868,283
+385,806
| +7% | +$8.9M | 0.01% | 1016 |
|
|
2023
Q4 | $119M | Sell |
5,482,477
-2,213,578
| -29% | -$43.9M | 0.01% | 943 |
|
|
2023
Q3 | $158M | Sell |
7,696,055
-1,093,682
| -12% | -$31.6M | 0.01% | 794 |
|
|
2023
Q2 | $413M | Buy |
8,789,737
+1,706,204
| +24% | +$84.9M | 0.03% | 471 |
|
|
2023
Q1 | $297M | Buy |
7,083,533
+532,042
| +8% | +$22.9M | 0.03% | 561 |
|
|
2022
Q4 | $250M | Buy |
6,551,491
+233,957
| +4% | +$8.93M | 0.02% | 609 |
|
|
2022
Q3 | $247M | Buy |
6,317,534
+340,441
| +6% | +$13.2M | 0.03% | 595 |
|
|
2022
Q2 | $193M | Buy |
5,977,093
+345,568
| +6% | +$11.6M | 0.02% | 702 |
|
|
2022
Q1 | $186M | Buy |
5,631,525
+140,951
| +3% | +$5.3M | 0.01% | 811 |
|
|
2021
Q4 | $234M | Sell |
5,490,574
-146,510
| -3% | -$6.13M | 0.02% | 745 |
|
|
2021
Q3 | $250M | Sell |
5,637,084
-1,224,575
| -18% | -$56.2M | 0.02% | 713 |
|
|
2021
Q2 | $390M | Sell |
6,861,659
-1,895,630
| -22% | -$134M | 0.03% | 528 |
|
|
2021
Q1 | $655M | Buy |
8,757,289
+950,590
| +12% | +$77.9M | 0.06% | 335 |
|
|
2020
Q4 | $675M | Buy |
7,806,699
+10,559
| +0.1% | +$778K | 0.06% | 318 |
|
|
2020
Q3 | $477M | Buy |
7,796,140
+8,468
| +0.1% | +$429K | 0.05% | 349 |
|
|
2020
Q2 | $324M | Buy |
7,787,672
+1,004
| +0% | +$36.4K | 0.04% | 433 |
|
|
2020
Q1 | $224M | Buy |
7,786,668
+14,039
| +0.2% | +$813K | 0.03% | 470 |
|
|
2019
Q4 | $561M | Buy |
7,772,629
+24,081
| +0.3% | +$2.96M | 0.06% | 293 |
|
|
2019
Q3 | $1.09B | Buy |
7,748,548
+76,394
| +1% | +$12.8M | 0.13% | 155 |
|
|
2019
Q2 | $1.4B | Buy |
7,672,154
+63,915
| +0.8% | +$10.9M | 0.16% | 111 |
|
|
2019
Q1 | $1.21B | Buy |
7,608,239
+575,163
| +8% | +$83.3M | 0.14% | 131 |
|
|
2018
Q4 | $674M | Buy |
7,033,076
+33,432
| +0.5% | +$3.83M | 0.09% | 203 |
|
|
2018
Q3 | $989M | Buy |
6,999,644
+22,266
| +0.3% | +$3.44M | 0.11% | 169 |
|
|
2018
Q2 | $1.09B | Buy |
6,977,378
+110,687
| +2% | +$17.4M | 0.13% | 155 |
|
|
2018
Q1 | $1.11B | Buy |
6,866,691
+629,172
| +10% | +$107M | 0.13% | 155 |
|
|
2017
Q4 | $1.03B | Buy |
6,237,519
+621,357
| +11% | +$60.2M | 0.12% | 174 |
|
|
2017
Q3 | $350M | Buy |
5,616,162
+14,219
| +0.3% | +$1.12M | 0.04% | 468 |
|
|
2017
Q2 | $446M | Buy |
5,601,943
+11,416
| +0.2% | +$825K | 0.06% | 344 |
|
|
2017
Q1 | $397M | Buy |
5,590,527
+15,451
| +0.3% | +$905K | 0.05% | 404 |
|
|
2016
Q4 | $285M | Buy |
5,575,076
+100,596
| +2% | +$4.74M | 0.04% | 515 |
|
|
2016
Q3 | $252M | Buy |
5,474,480
+670,048
| +14% | +$27.3M | 0.03% | 568 |
|
|
2016
Q2 | $145M | Buy |
4,804,432
+6,204
| +0.1% | +$207K | 0.02% | 805 |
|
|
2016
Q1 | $154M | Buy |
4,798,228
+469,958
| +11% | +$16.5M | 0.02% | 777 |
|
|
2015
Q4 | $252M | Buy |
4,328,270
+6,281
| +0.1% | +$311K | 0.03% | 556 |
|
|
2015
Q3 | $183M | Buy |
4,321,989
+57,500
| +1% | +$3.54M | 0.03% | 670 |
|
|
2015
Q2 | $311M | Buy |
4,264,489
+393,186
| +10% | +$25.3M | 0.04% | 487 |
|
|
2015
Q1 | $194M | Buy |
3,871,303
+2,410
| +0.1% | +$104K | 0.02% | 707 |
|
|
2014
Q4 | $142M | Buy |
3,868,893
+12,104
| +0.3% | +$451K | 0.02% | 845 |
|
|
2014
Q3 | $121M | Buy |
+3,856,789
| New | +$112M | 0.02% | 878 |
|
Other funds holding SAGE
IA
HNB
Fidelity Investments's SAGE Position: Q3 2025 in Review
Fidelity Investments sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 4,133 shares — an estimated $37.7K sold.
Fidelity Investments first reported a position in SAGE in Q3 2014 and held it in 44 quarters. The position peaked at $1.4B in Q2 2019. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- Fidelity Investments reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- Fidelity Investments sold 4,133 Sage Therapeutics shares in Q3 2025, an estimated $37.7K.
- Fidelity Investments first reported a position in Sage Therapeutics in Q3 2014 and held it in 44 quarters.
- Fidelity Investments's Sage Therapeutics position peaked at $1.4B in Q2 2019.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on Fidelity Investments's 13F filing for Q3 2025, filed 13 Nov 2025.